Literature DB >> 12558536

Antenatal screening for postnatal depression: a systematic review.

M-P Austin1, J Lumley.   

Abstract

OBJECTIVE: To describe the screening properties of the antenatal tools which have been developed to predict depression after birth and to summarize the implications of the findings for antenatal screening.
METHOD: Systematic review and secondary analysis of published papers.
RESULTS: Sixteen studies including sufficient data for the calculation of screening properties were identified. The majority developed a study-specific screening instrument. Outcome assessments used the Edinburgh Postnatal Depression Scale or standardized diagnostic psychiatric interviews, or both. In the two largest population-based studies, the proportion of women screening as positive ('at risk' of postnatal depression) was 16 and 52%, respectively, and of these only 35 and 8% actually developed depression after birth.
CONCLUSION: No screening instrument(s) met the criteria for routine application in the antenatal period. Factors that may have affected poor sensitivity and positive predictive values include the exclusion of key domains in predicting risk, particularly personality, a past history of abuse and postnatal events, the contribution of which may be being under-estimated in studies evaluating antenatal risk prediction tools.

Entities:  

Mesh:

Year:  2003        PMID: 12558536     DOI: 10.1034/j.1600-0447.2003.02024.x

Source DB:  PubMed          Journal:  Acta Psychiatr Scand        ISSN: 0001-690X            Impact factor:   6.392


  33 in total

Review 1.  Investigating outcomes following the use of selective serotonin reuptake inhibitors for treating depression in pregnancy: a focus on methodological issues.

Authors:  Luke E Grzeskowiak; Andrew L Gilbert; Janna L Morrison
Journal:  Drug Saf       Date:  2011-11-01       Impact factor: 5.606

2.  Antenatal depression case finding by community health workers in South Africa: feasibility of a mobile phone application.

Authors:  Alexander C Tsai; Mark Tomlinson; Sarah Dewing; Ingrid M le Roux; Jessica M Harwood; Mickey Chopra; Mary Jane Rotheram-Borus
Journal:  Arch Womens Ment Health       Date:  2014-03-30       Impact factor: 3.633

Review 3.  Psychosocial and psychological interventions for prevention of postnatal depression: systematic review.

Authors:  Cindy-Lee Dennis
Journal:  BMJ       Date:  2005-07-02

4.  An intervention to reduce postpartum depressive symptoms: a randomized controlled trial.

Authors:  Elizabeth A Howell; Susan Bodnar-Deren; Amy Balbierz; Holly Loudon; Pablo A Mora; Caron Zlotnick; Jason Wang; Howard Leventhal
Journal:  Arch Womens Ment Health       Date:  2013-09-10       Impact factor: 3.633

5.  Community-based prenatal screening for postpartum depression in a South African township.

Authors:  Kristin J Hung; Mark Tomlinson; Ingrid M le Roux; Sarah Dewing; Mickey Chopra; Alexander C Tsai
Journal:  Int J Gynaecol Obstet       Date:  2014-04-02       Impact factor: 3.561

6.  Prevalence and correlates of depression in pregnancy among Turkish women.

Authors:  Zehra Golbasi; Meral Kelleci; Gursum Kisacik; Ali Cetin
Journal:  Matern Child Health J       Date:  2009-02-24

7.  Family-centred HIV interventions: lessons from the field of parental depression.

Authors:  Mark Tomlinson
Journal:  J Int AIDS Soc       Date:  2010-06-23       Impact factor: 5.396

Review 8.  Anxiety disorders in pregnancy.

Authors:  Bavanisha Vythilingum
Journal:  Curr Psychiatry Rep       Date:  2008-08       Impact factor: 5.285

9.  Optimistic outlook regarding maternity protects against depressive symptoms postpartum.

Authors:  Thalia K Robakis; Katherine E Williams; Susan Crowe; Heather Kenna; Jamie Gannon; Natalie L Rasgon
Journal:  Arch Womens Ment Health       Date:  2014-08-05       Impact factor: 3.633

10.  The relationship between women's attachment style and perinatal mood disturbance: implications for screening and treatment.

Authors:  Catherine Monk; Kristin L Leight; Yixin Fang
Journal:  Arch Womens Ment Health       Date:  2008-05-21       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.